NO940084L - Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler - Google Patents

Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler

Info

Publication number
NO940084L
NO940084L NO940084A NO940084A NO940084L NO 940084 L NO940084 L NO 940084L NO 940084 A NO940084 A NO 940084A NO 940084 A NO940084 A NO 940084A NO 940084 L NO940084 L NO 940084L
Authority
NO
Norway
Prior art keywords
bdnf
molecules
members
neuron diseases
treating motor
Prior art date
Application number
NO940084A
Other languages
English (en)
Norwegian (no)
Other versions
NO940084D0 (no
Inventor
Vivien Wong
Czeslaw Radziejewski
Peter Distefano
Original Assignee
Regeneron Pharma
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Max Planck Gesellschaft filed Critical Regeneron Pharma
Publication of NO940084D0 publication Critical patent/NO940084D0/no
Publication of NO940084L publication Critical patent/NO940084L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physical Water Treatments (AREA)
  • Water Treatment By Electricity Or Magnetism (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Water Treatment By Sorption (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO940084A 1991-07-10 1994-01-10 Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler NO940084L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72770491A 1991-07-10 1991-07-10
PCT/US1992/004228 WO1993001300A1 (fr) 1991-07-10 1992-05-19 Methodes de traitement de maladies des neurones moteurs utilisant des elements de la famille des molecules bdnf/nt-3/ngf

Publications (2)

Publication Number Publication Date
NO940084D0 NO940084D0 (no) 1994-01-10
NO940084L true NO940084L (no) 1994-03-08

Family

ID=24923677

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940084A NO940084L (no) 1991-07-10 1994-01-10 Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler

Country Status (20)

Country Link
EP (2) EP0593516B1 (fr)
JP (1) JPH06509094A (fr)
CN (1) CN1065768C (fr)
AT (1) ATE202939T1 (fr)
AU (2) AU675409B2 (fr)
CA (1) CA2113083A1 (fr)
DE (1) DE69231930T2 (fr)
DK (1) DK0593516T3 (fr)
ES (1) ES2157903T3 (fr)
FI (1) FI940098A (fr)
GR (1) GR3036776T3 (fr)
HU (1) HUT70275A (fr)
IE (1) IE921602A1 (fr)
IL (1) IL101928A0 (fr)
NO (1) NO940084L (fr)
PT (1) PT100501A (fr)
RU (1) RU94016525A (fr)
SK (1) SK2694A3 (fr)
WO (1) WO1993001300A1 (fr)
ZA (1) ZA923639B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4535993A (en) * 1992-06-12 1994-01-04 Regeneron Pharmaceuticals, Inc. Therapeutic and diagnostic methods based on neurotrophin-4 expression
FR2717496B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
CN1112215C (zh) * 1999-12-28 2003-06-25 潘晓东 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途
AU5945301A (en) * 2000-05-05 2001-11-20 Res Foundation Of City Univers Methods for stimulating nervous system regeneration and repair by regulating arginase i and polyamine synthesis
EP2913393B8 (fr) * 2004-11-17 2020-02-26 Seneca Biopharma, Inc. Transplantation de cellules neurales humaines pour le traitement d'affections neurodégénératives
WO2008156418A1 (fr) * 2007-06-19 2008-12-24 Astrazeneca Ab Procédé de criblage ou de diagnostic du syndrome de post-poliomyélite et de la fibromyalgie
CA2695997C (fr) * 2007-08-10 2016-11-22 Regeneron Pharmaceuticals, Inc. Anticorps humains anti-facteur de croissance nerveux humain de haute affinite
WO2014111525A2 (fr) 2013-01-18 2014-07-24 Anaxomics Biotech, Sl Nouvelles polythérapies pour le traitement de maladies du système nerveux
US10349890B2 (en) 2015-06-26 2019-07-16 C. R. Bard, Inc. Connector interface for ECG-based catheter positioning system
WO2023164311A2 (fr) * 2022-02-28 2023-08-31 Bioincept, Llc Compositions et méthodes de traitement de la sclérose latérale amyotrophique (sla) et de troubles associés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor
IL95511A (en) * 1989-08-30 2000-10-31 Max Planck Gesellschaft Neurotrophin-3 a novel neurotrophic factor related to nerve growth and brain derived neurotrophic factor
IE903130A1 (en) * 1989-09-15 1991-03-27 Regeneron Pharma Ciliary neurotrophic factor

Also Published As

Publication number Publication date
SK2694A3 (en) 1995-02-08
DK0593516T3 (da) 2001-09-17
FI940098A (fi) 1994-03-10
CN1065768C (zh) 2001-05-16
EP0755682A1 (fr) 1997-01-29
ZA923639B (en) 1993-02-24
AU675409B2 (en) 1997-02-06
DE69231930D1 (de) 2001-08-16
IE921602A1 (en) 1993-01-13
HU9400063D0 (en) 1994-06-28
CA2113083A1 (fr) 1993-01-21
CN1071585A (zh) 1993-05-05
NO940084D0 (no) 1994-01-10
EP0593516B1 (fr) 2001-07-11
WO1993001300A1 (fr) 1993-01-21
RU94016525A (ru) 1996-06-10
AU7067696A (en) 1997-01-16
DE69231930T2 (de) 2002-04-11
AU2009592A (en) 1993-02-11
HUT70275A (en) 1995-09-28
FI940098A0 (fi) 1994-01-10
IL101928A0 (en) 1992-12-30
ATE202939T1 (de) 2001-07-15
EP0593516A1 (fr) 1994-04-27
PT100501A (pt) 1993-09-30
GR3036776T3 (en) 2002-01-31
EP0593516A4 (fr) 1995-01-18
JPH06509094A (ja) 1994-10-13
ES2157903T3 (es) 2001-09-01

Similar Documents

Publication Publication Date Title
NO940084L (no) Fremgangsmåte for behandling av motor-neuron sykdommer ved anvendelse av medlemmer av BDNF/NT-3/NGF familien av molekyler
Gatz et al. Psychological interventions with older adults.
GR3035001T3 (en) Nitric oxide donor composition and method for treatment of anal disorders
DE69428130T2 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69634301D1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
AU1416688A (en) Method of treating multiple sclerosis with chalcone derivatives
FI943028A0 (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
DE3770465D1 (de) Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
DE3782346D1 (de) Verwendung von chinolon und naphthyridin-antibiotika zur herstellung von ophthalmischen arzneimitteln.
Avery et al. Bright dawn simulation compared with bright morning light in the treatment of winter depression
Gordon The relationship between language and behaviour.
ATE186841T1 (de) Methode zum erzeugen von analgie mittels neurotrophine
Boyer Approaching cross-cultural psychotherapy.
Hoogduin et al. Double-Blind Research Psychotherapy
Sokolova On the problem of psychotherapy of borderline personality disorders
RU94006635A (ru) Способ коррекции функциональных состояний
UA20012A (uk) Спосіб лікуваhhя постекстракційhої запальhої ексудативhої реакції у хворих hа катаракту
RU96117545A (ru) Способ лечения диабетической ретинопатии
Gauron et al. A married couple in separate therapy groups
Simon Plato on the Mind-Body Problem
Semke Feasibility of pathogenetic therapy for hysteria
RU93037460A (ru) Способ лечения псориаза и пузырчатки
RU96101453A (ru) Способ лечения заболеваний
RU5055525A (ru) Способ лечения заикания